131 related articles for article (PubMed ID: 38407508)
1. Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study.
Li J; Gong X; Liu X; Liu X; Szeto K; Chen X
Pharmacol Res Perspect; 2024 Apr; 12(2):e1165. PubMed ID: 38407508
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
Coleman M; Belada D; Casasnovas RO; Gressin R; Lee HP; Mehta A; Munoz J; Verhoef G; Corrado C; DeMarini DJ; Zhao W; Li J; Fay K
Leuk Lymphoma; 2021 Feb; 62(2):368-376. PubMed ID: 33140664
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Phillips TJ; Avigdor A; Gurion R; Patti C; Corradini P; Tani M; Mehta A; Lossos IS; Zinzani PL; Thieblemont C; Jurczak W; Zheng F; Rappold E; Zhao W; Jiang P; Johnson P
Blood Adv; 2024 Feb; 8(4):867-877. PubMed ID: 38113459
[TBL] [Abstract][Full Text] [Related]
4. Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study.
Fukuhara N; Suehiro Y; Kato H; Kusumoto S; Coronado C; Rappold E; Zhao W; Li J; Gilmartin A; Izutsu K
Cancer Sci; 2022 May; 113(5):1702-1711. PubMed ID: 35201656
[TBL] [Abstract][Full Text] [Related]
5. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Forero-Torres A; Ramchandren R; Yacoub A; Wertheim MS; Edenfield WJ; Caimi P; Gutierrez M; Akard L; Escobar C; Call J; Persky D; Iyer S; DeMarini DJ; Zhou L; Chen X; Dawkins F; Phillips TJ
Blood; 2019 Apr; 133(16):1742-1752. PubMed ID: 30803990
[TBL] [Abstract][Full Text] [Related]
6. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hamadani M; Coleman M; Boccia R; Duras J; Hutchings M; Zinzani PL; Cordoba R; Oreiro MB; Williams V; Liu H; Stouffs M; Langmuir P; Sancho JM
Hematol Oncol; 2023 Dec; 41(5):848-857. PubMed ID: 37496298
[TBL] [Abstract][Full Text] [Related]
8. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Zinzani PL; Trněný M; Ribrag V; Zilioli VR; Walewski J; Christensen JH; Delwail V; Rodriguez G; Venugopal P; Coleman M; Dartigeas C; Patti C; Pane F; Jurczak W; Taszner M; Paneesha S; Zheng F; DeMarini DJ; Jiang W; Gilmartin A; Mehta A
EClinicalMedicine; 2023 Aug; 62():102131. PubMed ID: 37599908
[TBL] [Abstract][Full Text] [Related]
9. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
[TBL] [Abstract][Full Text] [Related]
10. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
Trněný M; Avigdor A; McKinney MS; Paneesha S; Wahlin BE; Hrom JS; Cunningham D; Morley N; Canales M; Bastos-Oreiro M; Belada D; Devizzi L; Zheng F; DeMarini DJ; Jiang W; Jiang P; Lynch RC
EClinicalMedicine; 2023 Sep; 63():102130. PubMed ID: 37662520
[TBL] [Abstract][Full Text] [Related]
11. The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren's syndrome.
Scuron MD; Fay BL; Connell AJ; Oliver J; Smith PA
Int Immunopharmacol; 2021 Sep; 98():107904. PubMed ID: 34214886
[TBL] [Abstract][Full Text] [Related]
12. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
14. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
15. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies.
Gong X; Ji T; Liu X; Chen X; Yeleswaram S
Pharmacol Res Perspect; 2022 Feb; 10(1):e00906. PubMed ID: 34951522
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Yacoub A; Borate U; Rampal RK; Ali H; Wang ES; Gerds AT; Hobbs G; Kremyanskaya M; Winton E; O'Connell C; Goel S; Oh ST; Schiller G; McCloskey J; Palmer J; Holmes H; Hager S; Assad A; Erickson-Viitanen S; Zhou F; Daver N
Blood Adv; 2024 Mar; 8(6):1515-1528. PubMed ID: 38290135
[TBL] [Abstract][Full Text] [Related]
18. Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
Passey C; Darbenzio R; Jou YM; Lynch M; Gupta M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1237-1244. PubMed ID: 27796540
[TBL] [Abstract][Full Text] [Related]
19. Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.
Dickinson A; Liu Y; Uvarov A; Peyret T; Marier JF; Chin C; Tran JQ
Clin Transl Sci; 2024 May; 17(5):e13808. PubMed ID: 38700272
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
